Articles by Susanne Keitel - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Susanne Keitel

Finished Product Monographs in the European Pharmacopoeia

The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products.
Jun 2, 2014

The European Pharmacopoeia Commission re-evaluates its policy on the development of monographs for finished drug products.

Control of Elemental Impurities

The European Pharmacopoeia Commission has decided to change its approach on elemental impurities.
Nov 2, 2013

The European Pharmacopoeia Commission has decided to change its approach on elemental impurities.

The Need for Pharmacopeial Harmonization

In the context of international trade, the need to develop global quality standards for medicines is increasing.
Apr 2, 2013

In the context of international trade, the need to develop global quality standards for medicines is increasing.

Inside EDQM: Mass Serialization to Combat Counterfeit Drugs

Europe establishes new collaborative system to track products.
Oct 2, 2011

Europe establishes new collaborative system to track products.

Inside EDQM: Active Ingredient Inspection and Certification

The EDQM inspection program helps to ensure the quality of APIs on the European market.
Oct 2, 2010

The EDQM inspection program helps to ensure the quality of APIs on the European market.

Inside EDQM: The Role of the Pharmacopeia in a Globalized World

As drug manufacturing and standards grow, pharmacopeias must adapt to meet new challenges.
Apr 2, 2010

As drug manufacturing and standards grow, pharmacopeias must adapt to meet new challenges.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here